Corcept Therapeutics Incorporated, a California-based company, has been making waves in the drug discovery and development industry. The firm specializes in curing severe metabolic, oncologic, endocrine, and neurological disorders, making it a highly sought-after name in healthcare. One of its most significant achievements in this arena has been Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome. Those who have Type 2 diabetes or glucose intolerance and have failed surgery or aren't candidates for surgery have benefitted from this once-daily tablet, which has received much praise from patients and medical professionals alike. But the company's research and development efforts don't stop there. They are also currently in the process of developing relacorilant to treat patients with Cushing's syndrome, nab-paclitaxel in combination with relacorilant for the treatment of cortisol excess and advanced ovarian tumors, selective cortisol modulator for antipsychotic-induced weight gain and other disorders, and FKBP5 gene expression assays. Since its incorporation back in 1998, Corcept Therapeutics has established itself as an innovative healthcare provider, making strides in the advancement of life-changing treatments for the benefit of patients and medical professionals across America.
Corcept Therapeutics's ticker is CORT
The company's shares trade on the NASDAQ stock exchange
They are based in Menlo Park, California
There are 51-200 employees working at Corcept Therapeutics
It is corcept.com
Corcept Therapeutics is in the Healthcare sector
Corcept Therapeutics is in the Biotechnology industry
The following five companies are Corcept Therapeutics's industry peers: